Patents by Inventor Alexander Fraser

Alexander Fraser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative
    Patent number: 10273249
    Abstract: There is provided a 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative which is useful in the treatment of respiratory syncytial virus (RSV) infection and for the prevention of disease associated with RSV infection. (Formula (1)).
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: April 30, 2019
    Assignee: PULMOCIDE LIMITED
    Inventors: Simon Fraser Hunt, Stuart Thomas Onions, Vladimir Sherbukhin, Euan Alexander Fraser Fordyce, Peter John Murray, Daniel William Brookes, Kazuhiro Ito, Peter Strong, Matthew Stephen Coates
  • HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS
    Publication number: 20190106425
    Abstract: The present invention relates to compounds of Formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
    Type: Application
    Filed: April 18, 2017
    Publication date: April 11, 2019
    Inventors: Allan Jordan, Rebecca Newton, Bohdan Waszkowycz, Jonathan Mark Sutton, George Hynd, Silvia Paoletta, Euan Alexander Fraser Fordyce
  • COMPOUNDS
    Publication number: 20190092791
    Abstract: There are provided 5,6-dihydro-4H-dithieno[3,2-b:2?,3?-d]azepine derivatives (as defined in the disclosure) which are useful in the treatment of RSV infection and for the prevention of disease associated with RSV infection.
    Type: Application
    Filed: April 7, 2017
    Publication date: March 28, 2019
    Applicant: Pulmocide Limited
    Inventors: Simon Fraser HUNT, Stuart Thomas ONIONS, Vladimir SHERBUKHIN, Euan Alexander Fraser FORDYCE, Jennifer Claire THOMAS, Peter John MURRAY, Matthew Stephen COATES, Daniel William BROOKES, Kazuhiro ITO, Peter STRONG
  • INHIBITOR OF p38 MAP KINASE
    Publication number: 20190092752
    Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.
    Type: Application
    Filed: July 11, 2018
    Publication date: March 28, 2019
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives
    Patent number: 10189863
    Abstract: There are provided 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives which are useful in the treatment of respiratory syncytial virus (RSV) infection and for the prevention of disease associated with RSV infection.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: January 29, 2019
    Assignee: PULMOCIDE LIMITED
    Inventors: Simon Fraser Hunt, Stuart Thomas Onions, Vladimir Sherbukhin, Euan Alexander Fraser Fordyce, Peter John Murray, Matthew Stephen Coates, Daniel William Brookes, Kazuhiro Ito, Peter Strong
  • 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives
    Patent number: 10160772
    Abstract: There are provided inter alia compounds which are intended to treat or prevent respiratory syncytial virus infections and associated disease particularly infections caused by the A and B strains thereof.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: December 25, 2018
    Assignee: PULMOCIDE LIMITED
    Inventors: Euan Alexander Fraser Fordyce, Simon Fraser Hunt, Stuart Thomas Onions, Vladimir Sherbukhin, Matthew Stephen Coates, Daniel William Brookes, Kazuhiro Ito, Peter Strong, John King-Underwood
  • Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative
    Publication number: 20180319820
    Abstract: There is provided a 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative which is useful in the treatment of respiratory syncytial virus (RSV) infection and for the prevention of disease associated with RSV infection. (Formula (1)).
    Type: Application
    Filed: July 12, 2018
    Publication date: November 8, 2018
    Inventors: Simon Fraser HUNT, Stuart Thomas ONIONS, Vladimir SHERBUKHIN, Euan Alexander Fraser FORDYCE, Peter John MURRAY, Daniel William BROOKES, Kazuhiro ITO, Peter STRONG
  • Inhibitor of p38 map kinase
    Patent number: 10045980
    Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: August 14, 2018
    Assignee: Respivert Ltd
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative
    Patent number: 10035810
    Abstract: There is provided a 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative which is useful in the treatment of respiratory syncytial virus (RSV) infection and for the prevention of disease associated with RSV infection. (Formula (1)).
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: July 31, 2018
    Assignee: PULMOCIDE LIMITED
    Inventors: Simon Fraser Hunt, Stuart Thomas Onions, Vladimir Sherbukhin, Euan Alexander Fraser Fordyce, Peter John Murray, Daniel William Brookes, Kazuhiro Ito, Peter Strong
  • NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVE
    Publication number: 20180179228
    Abstract: There is provided a 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative which is useful in the treatment of respiratory syncytial virus (RSV) infection and for the prevention of disease associated with RSV infection. (Formula (1)).
    Type: Application
    Filed: February 22, 2018
    Publication date: June 28, 2018
    Inventors: Simon Fraser HUNT, Stuart Thomas ONIONS, Vladimir SHERBUKHIN, Euan Alexander Fraser FORDYCE, Peter John MURRAY, Daniel William BROOKES, Kazuhiro ITO, Peter STRONG
  • PYRAZOLYL UREAS AS KINASE INHIBITORS
    Publication number: 20180118719
    Abstract: There are provided compounds of formula (I) as defined in the specification which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.
    Type: Application
    Filed: December 21, 2017
    Publication date: May 3, 2018
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Diane Venable, Iain Walters
  • 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative
    Patent number: 9926335
    Abstract: There is provided a 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative which is useful in the treatment of respiratory syncytial virus (RSV) infection and for the prevention of disease associated with RSV infection. (Formula (1)).
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: March 27, 2018
    Assignee: PULMOCIDE LIMITED
    Inventors: Simon Fraser Hunt, Stuart Thomas Onions, Vladimir Sherbukhin, Euan Alexander Fraser Fordyce, Peter John Murray, Daniel William Brookes, Kazuhiro Ito, Peter Strong
  • Pyrazolyl-ureas as kinase inhibitors
    Patent number: 9884845
    Abstract: There are provided compounds of formula (I) as defined in the specification, which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: February 6, 2018
    Assignee: Respivert Limited
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Diane Venable, Iain Walters
  • Novel 5,6-Dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives
    Publication number: 20170355718
    Abstract: There are provided inter alia compounds which are intended to treat or prevent respiratory syncytial virus infections and associated disease particularly infections caused by the A and B strains thereof.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 14, 2017
    Applicant: PULMOCIDE LIMITED
    Inventors: Euan Alexander Fraser FORDYCE, Simon Fraser HUNT, Stuart Thomas ONIONS, Vladimir SHERBUKHIN, Matthew Stephen COATES, Daniel William BROOKES, Kazuhiro ITO, Peter STRONG, John KING-UNDERWOOD
  • NOVEL 5,6-DIHYDRO-4H-BENZO[B]THIENO-[2,3-D]AZEPINE DERIVATIVES
    Publication number: 20170355717
    Abstract: There are provided 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives which are useful in the treatment of respiratory syncytial virus (RSV) infection and for the prevention of disease associated with RSV infection.
    Type: Application
    Filed: October 8, 2015
    Publication date: December 14, 2017
    Inventors: Simon Fraser HUNT, Stuart Thomas ONIONS, Vladimir SHERBUKHIN, Euan Alexander Fraser FORDYCE, Peter John MURRAY, Matthew Stephen COATES, Daniel William BROOKES, Kazuhiro ITO, Peter STRONG
  • Novel 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative
    Publication number: 20170305935
    Abstract: There is provided a 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative which is useful in the treatment of respiratory syncytial virus (RSV) infection and for the prevention of disease associated with RSV infection. (Formula (1)).
    Type: Application
    Filed: July 6, 2017
    Publication date: October 26, 2017
    Inventors: Simon Fraser HUNT, Stuart Thomas ONIONS, Vladimir SHERBUKHIN, Euan Alexander Fraser FORDYCE, Peter John MURRAY, Daniel William BROOKES, Kazuhiro ITO, Peter STRONG
  • Pyrazolyl-ureas as kinase inhibitors
    Patent number: 9701670
    Abstract: There are provided compounds of formula I, wherein R, R1, Ra, Rb, Q, X and Y have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: July 11, 2017
    Assignees: RESPIVERT LIMITED, TOPIVERT PHARMA LIMITED
    Inventors: Claire Anne Marie Cariou, Catherine Elisabeth Charron, Euan Alexander Fraser Fordyce, Daniel Hamza, Matthew Colin Thor Fyfe, Kazuhiro Ito, John King-Underwood, Peter John Murray, Stuart Thomas Onions, Stephen Malcolm Thom, Hayley Tegan Angela Watson, Jonathan Gareth Williams
  • INHIBITOR OF p38 MAP KINASE
    Publication number: 20170182039
    Abstract: A dry powder pharmaceutical formulation for inhalation including a compound of formula (I): that is 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((6-ethylpyrazin-2-yl)amino)pyridin-4-yl)methoxy)naphthalen-1-yl)urea or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof; and lactose as a topically acceptable diluent. An inhaler device containing the dry powder pharmaceutical formulation is also described.
    Type: Application
    Filed: March 13, 2017
    Publication date: June 29, 2017
    Inventors: ALISTAIR IAN LONGSHAW, EUAN ALEXANDER FRASER FORDYCE, STUART THOMAS ONIONS, JOHN KING-UNDERWOOD, JENNIFER VENABLE
  • Inhibitor of p38 MAP kinase
    Patent number: 9624196
    Abstract: A compound of formula (XV): wherein R1 represents an amino group, a protected amino group or nitro group; or a salt thereof. The compound is a p38 MAP kinase inhibitor. The compound and its pharmaceutically acceptable salts can be used for treatment of conditions, such as inflammatory diseases.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: April 18, 2017
    Assignees: RESPIVERT LTD., TOPIVERT PHARMA LTD.
    Inventors: Alistair Ian Longshaw, Euan Alexander Fraser Fordyce, Stuart Thomas Onions, John King-Underwood, Jennifer Venable
  • NOVEL COMPOUNDS
    Publication number: 20170057945
    Abstract: There are provided compounds of formula (I) as defined in the specification which are p38 MAP kinase inhibitors for use as medicaments for the treatment inter alia of inflammatory diseases.
    Type: Application
    Filed: February 13, 2015
    Publication date: March 2, 2017
    Inventors: Alistair Ian LONGSHAW, Euan Alexander Fraser FORDYCE, Stuart Thomas ONIONS, John KING-UNDERWOOD, Jennifer Diane VENABLE, Iain WALTERS